← Search another drug
PatientPulse · by PatientPartner
Darzalex daratumumab
High confidence
~54 public patient conversations, blogs, and reviews referenced; review-site ratings from Drugs.com (9 MM reviews, 11 Faspro reviews, 3 amyloidosis reviews).
Executive intelligence
The signal that moves starts & adherence
68%Positive sentiment in discussion
41,166FDA adverse-event reports
82%Flagged serious
45%Reports name female patients
The subcutaneous Faspro switch is the single highest-leverage moment: patients who make it report near-zero side effects and stay on therapy for years, yet the transition is inconsistently communicated and often patient-initiated.
- Darzalex delivers strong efficacy signals in patient voice (8.8-9.0 out of 10 on Drugs.com), with multiple reviewers citing deep remission and light-chain normalization as life-changing outcomes across MM and AL amyloidosis.
- The first IV infusion is a dominant anxiety trigger and a real adherence cliff; patients who survive it without severe reactions describe a rapid normalization of tolerance, especially after transitioning to subcutaneous Faspro.
- Infection susceptibility and mask-wearing as a permanent lifestyle change are under-communicated concerns that patients discover through peer networks rather than provider counseling, representing a key gap in patient services.
- Cost and insurance barriers, including prior authorization fights for combination regimens and a per-dose billed charge near $27,000, surface repeatedly and drive patients toward persistence in advocacy but risk treatment delays for the unnavigated.